drugset / Trial / NCT06106009

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

NCT06106009

Phase 1 Completed 117 enrolled Pfizer
RandomizedSequentialDouble-blindOther

Summary

The purpose of this clinical trial is to learn if the study medicine (called PF-07976016) is safe and how it goes in and out of the body in healthy people. The study may also explore if PF-07976016 has the potential to interact with another medicine called midazolam. In addition, the study may explore how PF-07976016 goes into the body of people who have obesity.

Timeline

Start
2023-10-27
Primary completion
2024-08-19
Completion
2024-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule Oral
Subject PF-07976016 Unknown

Indications

No indication recorded.